Polycyclic aromatic hydrocarbon (PAH)-DNA adducts may induce mutations that contribute to carcinogenesis. We evaluated potential associations between smoking and polymorphisms in PAH metabolism [CYP1A1 Ile 462
Introduction
Although prostate cancer is the most commonly diagnosed nonskin cancer and the third leading cause of cancer death among men in the United States (1), increasing age, ethnicity, and family history are the only established risk factors for this disease (2, 3) . African Americans, in particular, present at an earlier age and with more advanced disease and have higher mortality rates compared with Caucasians (4). Having a strong family history suggests the presence of a highly penetrant gene, but, to date, no single gene which can account for the majority of prostate cancers has been identified. Thus, the pathogenesis of prostate cancer likely involves a complex interplay between multiple low penetrant genetic and environmental factors.
Polycyclic aromatic hydrocarbon (PAH) exposure from cigarette smoke (5-7), grilled meats (8) , and various petroleum-related occupations (9-11) may play a role in prostate cancer. Although associations between smoking and these other PAH sources and prostate cancer have been equivocal, PAH require metabolic activation and subsequent binding to DNA (forming bulky ''PAH-DNA adducts'') to exert their carcinogenic action (12) . Therefore, functional polymorphisms in genes that metabolize PAHs and detoxify their reactive derivatives should be considered when evaluating potential effects of PAH exposure sources. Furthermore, many prior studies have relied upon self-reported measures from a single source; however, PAH-DNA adducts serve as a biological marker of the effective PAH dose from all sources, particularly when quantified in the target tissue. We previously observed that PAH-DNA adducts are present in human prostate cancer cells and vary with tumor characteristics (13) .
In terms of PAH metabolism, parent compounds, such as benzo(a)pyrene, are initially metabolized by CYP1A1 or CYP1B1 (14, 15) to an epoxide [benzo(a)pyrene -7,8-epoxide] and subsequently hydrolyzed by microsomal epoxide hydrolase (mEH) to a dihydrodiol [benzo(a)pyrene -7,8-dihydrodiol] . CYP1A1, CYP1B1, or CYP3A4 (16) can then transform the dihydrodiol to a highly reactive diol-epoxide [benzo(a)pyrene-7,8-dihydrodiol-9,10-epoxide, BPDE] that can covalently bind to DNA, creating a PAH [BPDE]-DNA adduct which may, in turn, induce mutation(s), predominantly in the form of G to T transversions (17) . Although mEH (18) and CYP1B1 (19) are expressed in the prostate, CYP1A1 may only be induced under androgen dependency (20) and CYP3A4 may require vitamin D receptor mediation (21) . Interestingly, CYP1B1 is highly expressed in the peripheral zone where most prostate cancers arise (22) . The CYP1A1 Ile 462 Val and CYP3A4 A(À392)G polymorphisms have variant alleles with higher enzymatic activity compared with their respective wild-type alleles (23, 24) , and the activity of the CYP1B1 Ala 119 Ser and Leu 432 Val variants is substrate dependent with 432 Val/ 119 Ala, having slightly higher activity in metabolizing benzo(a)pyrene-7,8-dihydrodiols but slightly lower activity in metabolizing parent benzo(a)pyrene than 432 Leu/ 119 Ala (15) . Effects of the mEH Try 113 His and mEH His 139 Arg polymorphisms remain unclear; an earlier study reported that 113 Tyr/ 139 Arg had the most activity in hydrolyzing benzo(a)pyrene-epoxides to benzo(a)-pyrene-dihydrodiols (25) , but recent work shows the 113 Tyr/ 139 His combination may be the most active (26) . The CYP1A1 Ile 462 Val, CYP1B1 Leu 432 Val, CYP3A4 A(À392)G polymorphisms have been equivocally associated with prostate cancer (27) (28) (29) (30) (31) , which may be attributed, in part, to heterogeneity in PAH exposure. In prostate cancer, only one (null) finding has been reported for the mEH His 139 Arg polymorphism (32) and no studies have examined the mEH Tyr 113 His polymorphism. Before a PAH-diol-epoxide metabolite can adduct DNA, it may be detoxified by enzymes in the glutathione S-transferase (GST) family. In particular, GSTM1 and GSTP1 exhibit substrate specificity for PAH-diol-epoxides (33) and are expressed in the prostate (34) (35) (36) . Although GSTT1 is highly expressed in the prostate (37), it does not seem to be involved in PAH metabolite conjugation (38 (40, 41) . GSTM1 has a polymorphism that leads to complete loss of protein (GSTM1 null deletion), and this polymorphism, as well as GSTP1 Ile 105 Val, has been associated with increased prostate cancer risk in some studies (42) (43) (44) but decreased risk in others (45) (46) (47) , which may also be due, in part, to heterogeneity in PAH exposure.
Although associations between a few of the aforementioned polymorphisms in metabolism and conjugation genes and PAH-DNA adduct levels have been examined in human lung (48) and breast (49, 50) cancer tissues and differences in PAH-DNA adduct levels by race in mononuclear cells have been reported (51) , no prior studies have evaluated effects of these polymorphisms on adduct levels in human prostate cancer tissues. Therefore, in this study, we extend our earlier work 
Materials and Methods
Study Population. The study design and population have been described elsewhere (13) . Briefly, the study population was composed of men from a larger case (n = 637) and control (n = 244) study who were diagnosed with prostate cancer and underwent radical prostatectomy (n = 395; 62.0%) or transurethral resection (n = 5; 0.7%) for treatment within the Henry Ford Health System, a network of facilities comprising an 800-bed hospital in the City of Detroit, Michigan, three smaller hospitals in surrounding suburbs, and 31 medical clinics located throughout the Metropolitan Detroit area. Potential cases that indicated primary adenocarcinoma of the prostate were identified through the Henry Ford Health System pathology reports. Two of the 395 cases used in this study were initially enrolled as controls. Cases were eligible for the larger case-control study if they used the Henry Ford Health System as their primary source of health care, lived in the study area at time of recruitment (2001) (2002) (2003) (2004) , and had no previous history of prostate cancer.
Subjects who agreed to participate were also asked to complete a two-part interviewer-administered risk factor questionnaire (the first part was conducted over the phone; the second part was done in person) and donate a blood sample. All study protocols were approved by the Henry Ford Hospital Institutional Review Board. Clinical characteristics were obtained from medical records, and demographic, general health, and habit information (age, ethnicity, smoking) were determined from the questionnaire. Alcohol was estimated from a standardized food frequency questionnaire originally developed for two studies investigating the associations of dietary supplements and cancer risk: Vitamin and Lifestyle Cohort Study (52) and Selenium and Vitamin E Cancer Prevention Trial (53).
Genotyping. Standard venipuncture was used to collect blood samples from all study participants in tubes with EDTA as an anticoagulant. Genomic DNA was extracted from buffy coats using QIAmp DNA Blood kit (Qiagen Inc., Valencia, CA). All purified DNA samples were diluted to a constant DNA concentration in 10 mmol/L Tris, 1 mmol/L EDTA buffer (pH 8).
mEH His 139 Arg (rs2234922) and CYP1B1 Leu 432 Val (rs1056836) were assayed by RFLP using primer and assay conditions that have been previously described (26, 54). His (rs1051740) polymorphisms were assayed using the GenomeLab SNP-Primer Extension assay (Beckman Coulter, Fullerton, CA) and analyzed on a CEQ 8000 Genetic Analysis System (Beckman Coulter). PCR was done using the primers (Invitrogen, Carlsbad, CA) 5 ¶-GAACTGC-CACTTCAGCTG-3 ¶ (forward) and 5 ¶-CTGGCTGCCCAACCA-GA-3 ¶ (reverse) for CYP1A1, 5 ¶-GTGCTGGCCACTGTGCATGT-3 ¶ (forward) and 5 ¶-ACACGGCACTCATGACGTTG-3 ¶ (reverse) for CYP1B1, and 5 ¶-GATCGATAAGTTCCGTTTCACC-3 ¶ (forward) and 5 ¶-TCATTGGACTGGATGGTGCATT-3 ¶ (reverse) for mEH. PCR was done in a 20-AL reaction with 40 ng DNA, 20 pmol of forward and reverse primers, 1.5 mmol/L MgCl 2 , 0.25 mmol/L deoxynucleotide triphosphate, and 1.5 units AmpliTaq Gold DNA polymerase (Applied Biosystems, Foster City, CA). For CYP1B1 amplification, 2 AL DMSO was added to each reaction. PCR conditions were 10 min at 95jC, followed by 30 cycles of 95jC for 30 s, 61jC (CYP1A1) or 60jC (CYP1B1 119 and mEH 113 ) for 35 s, and 72jC for 1 min, followed by a 6-min extension at 72jC. PCR reactions (6 AL) were cleaned with 2 units of shrimp alkaline phosphatase (Promega, Madison, WI) and 1 unit of Exonuclease I (New England Biolabs, Ipswich, MA) for 2 h at 37jC, followed by heat inactivation at 75jC for 30 min. The SNP primer extension assay was done using the GenomeLab SNP-Primer Extension kit (Beckman Coulter) according to manufacturer's instructions. SNP interrogation primers used were 5 ¶-ATGGGCAAGCGGAAGTGTATCGG-TGAGACC-3 ¶ (forward) and 5 ¶-AAAGACCTCCCAGCGGG-CAA-3 ¶ (reverse) for CYP1A1 Ile The GSTM1 polymorphism, which results in the presence (nondeleted) or absence (null deletion) of the enzyme, was detected by a PCR product coamplified with h-globin as a positive internal control within a multiplex PCR as previously described (42) .
To ensure quality control of all genotyping results, 5% of the samples were randomly selected and genotyped by a second investigator and 1% of the samples were sequenced using a 377 ABI automated sequencer. PAH-DNA Adduct Scoring. H&E stained slides of study cases were reviewed by the study pathologist (Adnan T. Savera) to confirm the diagnosis and to identify a paraffin block with sufficient prostate tumor and nontumor prostate tissue from the radical prostatectomy for staining. For each patient sample, we used a microtome to cut five consecutive sections (5-Amol/L thick) from the tissue block. One slide was H&E stained and examined by the study pathologist who circled separate areas of prostate tumor and nontumor prostate cell populations to be used for subsequent PAH-DNA adduct scoring. The immunohistochemical assay for PAH-DNA adducts was carried out as described previously (13, 49, 56) . This chemical assay uses the monoclonal 5D11 antibody, which in cell culture studies has been shown to produce strongly correlated staining levels (r = 0.99; P = 0.011) with the treatment dose of benzo(a)pyrene diol epoxide (57, 58) . Consistent with our previous (13) and other prior studies (49, 59) using immunohistochemical assays to measure PAH-DNA adducts, we report our results in absorbance units which provides a measure of the relative intensity of staining.
For each prostate specimen, two technicians independently scored 50 epithelial cells (five fields with 10 cells per field scored) in the two areas (tumor and nontumor) circumscribed by the study pathologist. Scored cells were selected to be representative, in terms of intensity, of the cells in the field, and the mean of the two technicians' scores was used. The dual scoring technique has proved to yield a high test-retest reliability in prostate cells (13) . PAH-DNA adduct data were standardized across experiments using a series of two prostate ''control'' slides (taken from two separate prostate specimens provided by men with prostate cancer who underwent radical prostatectomy but were not part of the study population) that were run across all batches.
Statistical Analysis. We tested the distribution of PAH-DNA adduct levels in prostatic epithelial tumor and adjacent nontumor cells for normality using the Shapiro-Wilk test statistic. Paired t tests were used to determine if PAH-DNA adduct levels between tumor and nontumor cells deviated significantly from zero. Correlations between explanatory variables and PAH-DNA adduct levels in tumor and nontumor cells were calculated using the parametric Pearson or (60) . We then used generalized linear regression models to estimate the association between genotypes and PAH-DNA adduct levels in prostate tumor cells and adjacent nontumor cells in the total study population and in Caucasians and African Americans, separately. Potential confounding by other factors including smoking, alcohol, and tumor characteristics [primary and total Gleason score, tumor volume, grade, prostate specific antigen (PSA) at diagnosis] was also evaluated. Models examining interactions included main effect terms (ethnicity; smoking; polymorphism under a dominant, recessive, or additive genetic model) and a multiplicative interaction term (e.g., ethnicity Â genotype). All P values are from two-sided tests. All analyses were undertaken with SAS (version 8.2, SAS Institute Inc., Cary, NC).
Results
Characteristics of the study population are provided in Table 1 . Approximately, 52.5% of the prostate cancer cases were Caucasian patients and 44.3% were African American patients. The mean age at diagnosis was 60.2 years with African American men diagnosed at a slightly younger age than Caucasian men. Approximately, 45.7% of the cases had a total Gleason score of 7 and 19.4% had a total Gleason score of >7. Although African Americans tended to present with a higher Gleason score and have greater tumor volume than Caucasians, these differences were not statistically significant. Similar to our earlier work that used 130 (13) of the 400 specimens in the present study, the distributions of PAH-DNA adduct levels in paired tumor and adjacent nontumor prostate specimens fell into two separate highly symmetrical normal distributions. Also consistent with our previous report (13), we observed a strong correlation between adduct levels in prostate tumor and nontumor prostate cells (r = 0.51; P < (Table 1) .
Neither ever or current smoking nor any of the PAH metabolism or conjugation polymorphisms, when examined individually, were statistically significantly associated with PAH-DNA adduct levels in the total sample (Table 2) . However, stratifying by race revealed that Caucasian ever smokers (Table 3) We also tested for joint effects between ethnicity, smoking, and genotypes by including an ethnicity Â smoking (or genotype) interaction term in the model (Table 3) . Using Caucasians as the reference group and African Americans as the risk group, we observed significant interactions between ethnicity and ever smoking [P value for interaction term (P int ) = 0.02] and between ethnicity and the mEH His We next examined joint PAH metabolism and conjugation genotype combinations on adduct levels based upon the function of the polymorphic alleles in key steps of the PAH metabolic pathway (Table 4 (Table 4) . Finally, carrying the ''high-risk'' genotype combination, the faster metabolism of PAH-diols to the most reactive PAH-diol-epoxide forms (CYP1B1 432 Val/Val and mEH 139 His/His or His/Arg) with lower capacity to conjugate these PAH-diol-epoxides (GSTP1 105 Ile/Ile), was associated with significantly increased adduct levels in the nontumor cells of Caucasians (0.2363 F 0.0132 versus 0.1920 F 0.0157; P = 0.05), but decreased adduct levels in non-tumor cells of African Americans (0.2121 F 0.0175 versus 0.3060 F 0.0408; P = 0.05). Cell sizes, however, continued to diminish with increasing genotype combination complexity and models with four or more polymorphisms were not estimable. We also examined the potential joint effects of ever (Table 5) and current smoking and PAH metabolism and conjugation genes on PAH-DNA adduct levels. Increased adducts were observed in tumor cells of Caucasian ever smokers carrying the potentially faster PAH-epoxide metabolizing mEH Although cell sizes became even smaller when examining the joint effects of smoking and combinations of polymorphisms, several notable associations were observed (Table 5) Val) genes and PAH-DNA adducts in tumor and adjacent nontumor prostate cells. Specifically, Caucasians who reported ever smoking had significantly increased PAH-DNA adduct levels compared with nonsmokers, but this effect was not observed in African Americans. The mEH 139 Arg/Arg genotype, which may potentially metabolize PAH-epoxides to PAH-dihydrodiols, more slowly (26) decreased adduct levels in both prostate tumor and nontumor prostate cells of Caucasians, but this effect was not found in African Americans. In addition, having one or two copies of the GSTP1 105 Val allele, which may more effectively conjugate the most reactive PAH-diol epoxides (40, 41) , was inversely associated with adduct levels in the tumor cells of Caucasians. Finally, carrying the putative high-risk genotype combination, the faster metabolism of PAH-dihydrodiols to their most reactive PAH-diol-epoxide forms (CYP1B1 432 Leu/Leu or Leu/Val and mEH 139 His/His or His/Arg) with lower capacity to conjugate these PAH-diol-epoxides (GSTP1 105 Ile/Ile), was associated with increased adduct levels in nontumor cells of Caucasians, but was associated with decreased adduct levels in non-tumor cells of African Americans. Our results are generally biologically plausible, given the expected activity of the alleles in key steps of the PAH metabolic pathway; however, functional studies are not entirely consistent and have focused on variation in one enzyme at a time, making it difficult to anticipate how variation in multiple enzymes affects PAH-DNA adduct levels. An initial in vitro study reported that the mEH 113 Consistent with our prior smaller study (13) , PAH-DNA adducts were higher in adjacent nontumor prostate cells compared with prostate tumor cells, irregardless of ethnicity. Similar effects have not been observed in other organs. For example, Rundle et al. (49) reported that tumor cells of breast cancer cases had slightly higher PAH-DNA adducts compared with adjacent nontumor cells. As we reported previously (13), our results suggest that adducts diminish as prostate cancer foci grow and become more poorly differentiated, which may be due, in part, to loss of estrogen receptor expression in tumor cells.
Differences between ethnic groups were not totally unexpected, because African Americans, compared with Caucasians generally present with prostate cancer at an earlier age and with more advanced disease, have higher prostate cancer mortality rates (4) and higher PAH-DNA adduct levels in mononuclear cells (51) . Associations between genetic polymorphisms and PAH-DNA adducts may differ by race due to differences in PAH exposure. Although we did not find a significant difference in smoking frequency between Caucasians and African Americans, PAH-DNA adduct levels, which measure the biologically effective PAH dose, were significantly increased in tumor cells of Caucasian, but not African American, ever smokers. Further stratification by genotype after adjusting for smoking status revealed that a putative high-risk genotype combination (CYP1B1 432 Val/Val and mEH 139 His/His or His/Arg and GSTP1 Ile/Ile) significantly increased adducts in Caucasians, but not African Americans who carried this genotype combination, suggesting that other PAH-exposure sources (e.g., diet and/or occupation) may contribute to adducts in the prostate. Furthermore, why some associations varied by cell type within an ethnic group is not entirely clear. Tumor characteristics may contribute to these varying results, and in our prior (13) and current work, PAH-DNA adduct levels tended to be lower in malignant cells, but those less-differentiated measures of tumor differentiation (primary and total Gleason score), tumor volume, tumor stage, and PSA at diagnosis into the multivariable models did not materially alter results. Alternatively, differences in the cellular microenvironment, such as aberrant methylation, may lead to differential expression of these enzymes, which are within tumor and nontumor cells and between Caucasians and African Americans, potentially affecting the importance of a polymorphism. For example, silencing of GSTP1 through hypermethylation has been observed in prostate cancer cells but not normal cells (61) , and GSTP1 hypermethylation has been observed to differ significantly between Caucasians and African Americans (62) . Interestingly, smoking, which contains substantial quantities of carcinogenic PAHs (63), modifies GSTP1 methylation in prostate cancer cells with current smokers having a significantly higher frequency than former or nonsmokers (64) . GSTP1 hypermethylation has been shown to modify 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine -DNA adduct levels in the prostate (65) , although in a recent study involving tumor and adjacent nontumor cells from hepatic carcinoma patients, no association between GSTP1 hypermethylation and PAH-DNA adducts was found (66) . Hypomethylation of the CYP1B1 promoter has been shown to increase its expression in prostate cancer but not normal cells (67) , although reports on how CYP1B1 hypomethylation affects PAH-DNA adduct levels are lacking. No prior studies have examined the effects of polymorphisms in PAH metabolism and conjugation genes and PAH-DNA adducts in prostate cancer cells; therefore, we can only compare our results to those from other tissues. Because immunoassay methods are more specific to PAH [BPDE and other similar structured]-DNA adducts whereas 32 P-postlabeling methods measure all hydrophobic DNA adducts (68) and results differ considerably between these two methods (69), we restrict our comparison to those studies using immunoassay methods similar to the one we used. In lung tumor tissue, the variant alleles of the CYP1A1 1*/2* (includes CYP1A1 Ile 462 Val) and the GSTM1 null deletion polymorphisms have been positively associated with (+)anti -BPDE -DNA adduct levels, and the effect was more pronounced in individuals with both polymorphisms (48) . In addition, carrying the GSTM1 null deletion has been shown to be positively associated with PAH-DNA adducts in tumor and adjacent nontumor cells obtained from breast cancer cases (49) , but this effect was not found in another study (50) . We did not find an effect with the GSTM1 null deletion polymorphism; however, we did observe significant individual and joint gene associations with the GSTP1 105 Val allele which may be more efficient than GSTM1 in conjugating the most reactive PAH-diolepoxides (33) .
Strengths of our study include its large sample size for this type of molecular evaluation and nearly equal distribution of Caucasians and African Americans. However, even larger samples are needed for effectively evaluating joint effects, particularly those involving two or more polymorphisms. Furthermore, we have treated ethnicity as a dichotomous variable when, in fact, it is really a continuous trait given the large degree of racial admixture in the United States. Incorporating and adjusting for ancestry informative markers in the analyses would help minimize any error induced by dichotomizing and help clarify interpretation of results. To obtain a more complete understanding of the underlying mechanisms of PAH-induced DNA damage in prostate cells, future work should include prostate specimens from ''healthy'' men without prostate cancer and should evaluate the influence of other sources of PAH exposure and DNA methylation and repair mechanisms on PAH-DNA adduct formation.
In summary, this is the first report describing the individual and joint associations between smoking and polymorphisms in PAH metabolism and conjugation genes and PAH-DNA adduct levels in tumor and nontumor prostate cells. Our results suggest that the association between smoking and PAH-DNA adducts differs by race and is modified by common genetic variants lending further insight to potential gene-environment interactions in prostate carcinogenesis.
